Ant International’s WorldFirst launches Enterprise Solution to Power Enterprises Global Growth

25.11.2025 04:59:00 CET | Business Wire | Press Release

WorldFirst, Ant International’s global account service provider, has launched an API-integrated and AI-driven solution tailored to global enterprises It leverages WorldFirst's unified global account, full-range financial services, and AI capabilities such as smarter treasury management to help streamline global funds distribution, unlock new revenue streams, and strengthen customer relationships.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251124796928/en/

WorldFirst CEO Clara Shi unveiled the new enterprise solution at Ant International’s Global Voyage Event in Singapore

McKinsey research predicts that within six years, digital platforms will facilitate over 30%—about $60 trillion—of global economic activity. Yet as enterprises operate digitally and expand globally, they face critical financial obstacles: inefficient payments, high costs, compliance complexity, and fragmented customer experience—all creating friction that hinders growth.

Built with security and efficiency at its core, the WorldFirst Enterprise Solution delivers a comprehensive suite of financial services accessible via an integrated API solution. It is designed to help global enterprises across e-commerce, the gig economy, SaaS, OTAs and other digital platforms to automate critical financial functions directly within their existing systems. The solution reflects WorldFirst’s strategy to combine global expertise with innovation to deliver future-ready financial rails.

Key features of the solution include:

Broader global connectivity: Tap into 200+ markets through WorldFirst's multi-currency World Account, with compliance backed by 60+ global licenses.
Stronger global spend solution: Launch and manage card issuing via World Card, plus mass payouts in 100+ currencies to bank accounts and wallets worldwide.
Smarter treasury management: Maximise revenue by Leveraging Ant International's Falcon AI forecast model, with >90% accuracy on liquidity and FX forecasting.
Faster global money movement: Powering 95% same-day global transfers & real-time settlement in 25 currencies through WorldFirst’s leading bank partnerships.
Simpler API+AI-native integration: Boost efficiency with a developer-centric AI toolkit for risk management, compliance, and 24/7 global support.

To overcome critical financial obstacles for its vast network of third-party sellers, a leading global e-commerce platform is leveraging WorldFirst’s Enterprise Solution for a comprehensive financial solution tailored to its ecosystem. This included a multi-currency wallet with automated eKYC/eKYB and global treasury management capabilities for collection, payment, and foreign exchange services.

Through seamless API integrations, the platform significantly improved the seller experience—cutting seller onboarding to under a day, strengthening compliance, and boosting global scalability with WorldFirst's extensive global coverage.

"Efficient payment and account services are no longer optional—they are fundamental to how platforms operate and compete globally," said Clara SHI, CEO of WorldFirst and Vice President of Ant International. "At WorldFirst, we built our API-integrated enterprise solution precisely to meet this critical need. It delivers a responsive and streamlined treasury experience, enabling digital platforms to lead in today’s fast-paced market. We remain dedicated to deepening the integration of fintech and global commerce, empowering businesses to seamlessly connect with the world."

About WorldFirst

WorldFirst offers cross-border payments and treasury services through its global business account. WorldFirst simplifies key financial operations, including international payments, collections, currency conversions, and treasury management, all via one unified account. Leveraging the technological strengths of its parent company, Ant International, WorldFirst delivers industry-leading transaction security and reliability. WorldFirst has supported over 1.5 million customers, enabling payments in 100+ currencies across more than 210 countries and regions. Learn more about WorldFirst at https://www.worldfirst.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20251124796928/en/

Contacts

Chloe ZHU
jingchong.zhu@ant-intl.com

Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

From Network Automation to Agentic NetOps: NetBrain Sets the Standard for Deploying AI in Network Operations29.5.2026 15:00:00 CEST | Press Release

NetBrain Technologies, Inc. today announced major new platform features that advance Agentic NetOps from an emerging category to operational reality. NetBrain's clients are already deploying agents that are diagnosing and remediating issues across complex multi-vendor enterprise networks. These new features further extend the platform with new agent tooling, cross-domain context, and open interfaces for the broader agentic enterprise. Early customer outcomes show the magnitude of the shift: A leading health insurer used NetBrain's Deep Diagnosis agent to diagnose and resolve a weeks old VPN connectivity issue in under five minutes. A large manufacturer resolved a critical device issue with a single prompt, isolating the root cause across the network path in under 20 minutes, saving hundreds of hours of engineer time, shrinking MTTR by more than 95%. A global telecommunications firm found NetBrain's context-grounded agents outperformed a stand-alone frontier LLM on a persistent firewall

Adtran resolves long-running patent litigation, reinforcing commitment to defend innovation29.5.2026 14:00:00 CEST | Press Release

Adtran today announced it has resolved a patent litigation matter, resulting in a full settlement and dismissal of all claims with prejudice. The case, initiated in 2020 by a non-practicing entity asserting five patents, was transferred to the US District Court for the Northern District of Alabama in 2021 following a successful motion by Adtran. Adtran subsequently filed counterclaims, including bad-faith patent assertion under Alabama statutory law. The settlement includes payment to Adtran to resolve its counterclaims. Terms of the agreement remain confidential. “This outcome reflects a disciplined and consistent approach to protecting our innovation and our customers,” said Justin Ferguson, SVP and general counsel at Adtran. “We take all claims seriously, but we will not hesitate to defend ourselves when assertions lack merit. Situations like this place unnecessary strain on technology providers and divert resources from advancing networks and services. By advancing our counterclaim

Meiji Seika Pharma Invests in GHIC’s Global Health Security Fund29.5.2026 13:00:00 CEST | Press Release

Meiji Seika Pharma Co., Ltd. (Headquarters: Tokyo, Japan; President and Representative Director: Toshiaki Nagasato) today announced that it has committed to invest in the Global Health Security Fund (GHSF), which is sponsored by Global Health Investment Corporation (GHIC), a New York-based nonprofit organization. Through this investment, Meiji Seika Pharma will support the acceleration of innovations addressing critical global health challenges, including pandemic preparedness and antimicrobial resistance (AMR). GHIC is a mission‑driven nonprofit organization that deploys private investment strategies to generate both global health impact and financial returns. GHIC recently closed its second fund in GHSF. With more than a decade of experience investing in the field of infectious disease, GHIC has contributed to addressing major global health challenges. Its portfolio companies have successfully commercialized more than a dozen products, collectively reaching over 600 million people wo

IFF Enters Into Agreement to Sell Its Food Ingredients Business to CVC29.5.2026 12:50:00 CEST | Press Release

IFF (NYSE: IFF), a global leader in flavors, fragrances, food ingredients, and health and biosciences, today announced that it has entered into an agreement to sell its Food Ingredients business to funds advised by CVC Capital Partners, a leading global private markets manager, in a transaction that values the business at approximately $4.3 billion, representing an enterprise value-to-EBITDA multiple of approximately 10x. As part of the transaction, IFF has chosen to retain an approximately 10% minority equity interest in the business, or approximately $200 million, permitting continued collaboration and cooperation between IFF and Food Ingredients and allowing IFF and its shareholders to participate in future value creation under its new ownership. The transaction marks a significant step in IFF’s portfolio transformation and is expected to strengthen the company’s focus on its innovation-driven businesses: Taste, Scent, and Health & Biosciences. Following the transaction, IFF will be

BeOne Medicines Establishes Standard for Long-Term Disease Control in CLL with BRUKINSA 78-Month Data at ASCO 202629.5.2026 12:00:00 CEST | Press Release

BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, is advancing the treatment paradigm in chronic lymphocytic leukemia (CLL) at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting. With extensive long-term follow-up, the SEQUOIA study of BRUKINSA® (zanubrutinib) reinforces its role as the foundational BTK inhibitor, showing sustained disease control over years of therapy. These findings are further supported by real-world evidence across three large analyses encompassing more than 250,000 patients, underscoring consistent effectiveness and safety in clinical practice. Additionally, BEQALZI™ (sonrotoclax), which was recently approved by the U.S. Food and Drug Administration, and its development in combination with BRUKINSA (ZS) highlight the potential for next-generation, time-limited treatment approaches in CLL. Amit Agarwal, M.D., Ph.D., Chief Medical Officer, Hematology, BeOne Medicines, said: “CLL is a disease patients live with

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom